Availability of Final Toxicological Profiles, 67871-67872 [E6-19857]
Download as PDF
<![CDATA[
Federal Register / Vol. 71, No. 226 / Friday, November 24, 2006 / Notices
cprice-sewell on PROD1PC66 with NOTICES
ACTION:
Notice.
SUMMARY: Notice is hereby given that
the Office of Research Integrity (ORI)
and the Assistant Secretary for Health
have taken final action in the following
case:
Clifford R. Robinson, Ph.D., University
of Delaware: Based on the reports of
investigations conducted by 3Dimensional Pharmaceuticals, Inc.
(3DP) and the University of Delaware
(UD) and additional analysis conducted
by ORI during its oversight review, the
U.S. Public Health Service (PHS) found
that Clifford R. Robinson, Ph.D.,
Assistant Professor, Department of
Chemistry and Biochemistry, UD,
engaged in misconduct in science
involving research supported by
National Institute of General Medical
Sciences (NIGMS), National Institutes of
Health (NIH), grants 1 R43 GM58950–01
and 2 R44 GM58950–02, ‘‘Four-helix
bundle analog of a G-protein coupled
receptor (C. Robinson, Principal
Investigator [P.I.]). The following grant
applications also were involved in Dr.
Robinson’s misconduct in science:
1 R43 GM62708–01, ‘‘Improved
method for protein refolding’’ (C.R.
Robinson, P.I.), submitted March 30,
2000; approved but not funded,
withdrawn.
1 P20 RR017716–01, ‘‘Design of
hierarchical recognition motifs,’’ Project
V, ‘‘Determinants of stability and
assembly of integral membrane
proteins’’ (C.R. Robinson, Project
Investigator), submitted March 1, 2002,
funded September 16, 2002, to August
30, 2007.
1 R01 GM074789–01, ‘‘Folding and
stability of integral membrane proteins’’
(C.R. Robinson, P.I.), submitted October
1, 2004; scored not competitive, not
funded.
1 R01 GM075891–01, ‘‘Membrane
protein expression, solubilization, and
refolding’’ (C.R. Robinson, P.I.),
submitted January 24, 2005; approved
but not funded, pending.
1 R21 GM07953–01, ‘‘Mini-receptor
analogs of GPCRs’’ (C.R. Robinson, P.I.),
submitted January 25, 2005; not funded.
Specifically, PHS found that Dr.
Robinson engaged in the following acts
of misconduct in science. With regard to
the following paragraphs numbered 1–6,
nothing herein shall be deemed as an
admission of liability on the part of Dr.
Robinson.
1. While at 3DP, Dr. Robinson
systematically substituted crystallized
chicken ovalbumin in place of b2–AR–
NQ and repeatedly provided these
crystalline preparations to other
scientists to conduct molecular
analyses. Dr. Robinson made false
VerDate Aug<31>2005
13:24 Nov 22, 2006
Jkt 211001
claims about his progress on
characterizing b2–AR–NQ and falsely
claimed to have supplied purified b2–
AR–NQ to 3DP staff in project team
meetings (PTM) held on at least five
occasions between July 14, 1998, and
July 7, 1999.
2. Dr. Robinson made multiple false
claims about his research on b2–AR–NQ
in NIH grant applications R44
GM58950–02, submitted April 1, 1999,
supplemental material for the same
application submitted on July 7, 1999,
and NIH grant application R43
GM62708–01, submitted March 30,
2000.
3. Dr. Robinson made similar claims
as in item 1 above concerning the wild
type form of b2–AR, by substituting
canine ovalbumin. Dr. Robinson’s false
claims were made to 3DP staff at PTM
meetings on at least three occasions
between September 7, 1999, and March
30, 2000, and in NIH grant application
R43 GM62708–01, and after moving to
UD, in NIH grant application 1 P20
RR017716–01, submitted on March 1,
2002.
4. Dr. Robinson was unable to
adequately produce recombinant b2–AR
in E. coli and made false claims at PTM
meetings in September and October
1999 that he had successfully expressed
active protein and had purified it for
crystallization trials. Dr. Robinson also
made false claims in NIH grant
applications R43 GM62708–01 and 1
R01 GM07589–01, submitted January
24, 2005, that he had purified large
amounts of b2–AR–NQ from E. coli and
that he had reconstituted the protein
into its native biologically active form.
5. Dr. Robinson made false claims
about his ability to produce, purify, and
characterize a recombinant fragment of
b2–AR–NQ containing four
transmembrane domains (b2–AR–4HB)
at PTM meetings in October 1998 and in
NIH grant applications R44 GM58950–
02 and 1 P20 RR017716–01.
6. Dr. Robinson falsified fluorescence
spectra and circular dichroism
measurements in Figure 7 (both left and
right panels) of NIH grant application
R44 GM58950–02 by substituting results
obtained with different proteins.
7. After moving to UD, Dr. Robinson
made false claims in NIH grant
application 1 P20 RR017716–01,
including presenting falsified data in
both panels of Figures V.5 (fluorescence
spectra and circular dichroism
measurements) and V.9 (falsified
experimental conditions).
8. While at UD, Dr. Robinson falsified
circular dichroism and fluorescence
data in NIH grant application 1 R01
GM074789–01 (Figures 5A, 5B, and 6)
and circular dichroism data in NIH
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
67871
grant applications 1 R01 GM075891–01
(Figure 6) and 1 R21 GM075953–01
(Figure 5).
9. In presentations at the Biophysical
Society annual meeting and a Cornell
University Consortium meeting, both in
1999, Dr. Robinson falsely represented
data obtained with cytochrome b562 as
being obtained with b2–AR.
Dr. Robinson has entered into a
Voluntary Exclusion Agreement in
which he has voluntarily agreed, for a
period of five (5) years, beginning on
October 23, 2006:
(1) To exclude himself from any
contracting or subcontracting with any
agency of the United States Government
and from eligibility for or involvement
in nonprocurement programs of the
United States Government as defined in
the debarment regulations at 45 CFR
Part 76; and
(2) to exclude himself from serving in
any advisory capacity to PHS, including
but not limited to service on any PHS
advisory committee, board, and/or peer
review committee, or as a consultant.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. E6–19888 Filed 11–22–06; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Toxic Substances and
Disease Registry
[ATSDR–226]
Availability of Final Toxicological
Profiles
Agency for Toxic Substances
and Disease Registry (ATSDR),
Department of Health and Human
Services (HHS).
ACTION: Notice of availability.
AGENCY:
SUMMARY: This notice announces the
availability of one new and five updated
final toxicological profiles of priority
hazardous substances comprising the
eighteenth set prepared by ATSDR.
FOR FURTHER INFORMATION CONTACT: Ms.
Olga Dawkins, Division of Toxicology
and Environmental Medicine, Agency
for Toxic Substances and Disease
Registry, Mailstop F–32, 1600 Clifton
Road, NE., Atlanta, Georgia 30333,
telephone (770) 488–3315. Electronic
access to these documents is also
E:\FR\FM\24NON1.SGM
24NON1
67872
Federal Register / Vol. 71, No. 226 / Friday, November 24, 2006 / Notices
available at the ATSDR Web site:
https://www.atsdr.cdc.gov/toxpro2.html.
SUPPLEMENTARY INFORMATION: The
Superfund Amendments and
Reauthorization Act of 1986 (SARA) (42
U.S.C. 9601 et seq.) amended the
Comprehensive Environmental
Response, Compensation, and Liability
Act of 1980 (CERCLA or Superfund) (42
U.S.C. 9601 et seq.) by establishing
certain requirements for ATSDR and the
U.S. Environmental Protection Agency
(EPA) with regard to hazardous
substances that are most commonly
found at facilities on the CERCLA
National Priorities List (NPL). Among
these statutory requirements is a
mandate for the Administrator of
ATSDR to prepare toxicological profiles
for each substance included on the
priority lists of hazardous substances.
These lists identified 275 hazardous
substances that ATSDR and EPA
determined pose the most significant
potential threat to human health. The
availability of the revised list of the 275
priority substances was announced in
the Federal Register on December 7,
2005 (70 FR 234). For prior versions of
the list of substances, see Federal
Register notices dated April 17, 1987
(52 FR 12866); October 20, 1988 (53 FR
41280); October 26, 1989 (54 FR 43619);
October 17, 1990 (55 FR 42067); October
17, 1991 (56 FR 52166); October 28,
1992 (57 FR 48801); February 28, 1994
(59 FR 9486); April 29, 1996 (61 FR
18744; November 17, 1997 (62 FR
61332); October 21, 1999 (64 FR 56792);
October 25, 2001 (66 FR 54014) and
November 7, 2003 (68 FR 63098).
Notice of the availability of drafts of
these five updated and one new
toxicological profiles for public review
and comment was published in the
Federal Register on October 22, 2004,
(69 FR 62049), with notice of a 90-day
public comment period for each profile,
starting from the actual release date.
Following the close of the comment
period, chemical-specific comments
were addressed, and, where appropriate,
changes were incorporated into each
profile. The public comments and other
data submitted in response to the
Federal Register notices bear the docket
control number ATSDR–205. This
material is available for public
inspection at the Division of Toxicology
and Environmental Medicine, Agency
for Toxic Substances and Disease
Registry, 1825 Century Boulevard,
Atlanta, Georgia (not a mailing address),
between 8 a.m. and 4:30 p.m., Monday
through Friday, except legal holidays.
Availability
This notice announces the availability
of one new and five updated final
toxicological profiles of priority
hazardous substances comprising the
eighteenth set prepared by ATSDR.
The following toxicological profiles
are now available through the U.S.
Department of Commerce, National
Technical Information Service (NTIS),
5285 Port Royal Road, Springfield,
Virginia 22161, telephone 1–800–553–
6847. There is a charge for these profiles
as determined by NTIS.
Eighteenth Set:
Toxicological profile
NTIS Order No.
1. Cyanide, Hydrogen cyanide, Sodium cyanide, Potassium cyanide ..............................................................
PB2007–100674
2. Dichlorobenzenes, 1, 2-Dichlorobenzene, 1,3-Dichlorobenzene, 1,4-Dichlorobenzene ...............................
PB2007–100672
3.
4.
5.
6.
PB2007–100676
PB2007–100675
PB2007–100673
PB2007–100671
1, 4-Dioxane * ................................................................................................................................................
Hydrogen Sulfide ...........................................................................................................................................
1, 1, 1-Trichloroethane ..................................................................................................................................
Vinyl Chloride ................................................................................................................................................
CAS No.
000057–12–5
000074–90–8
000143–33–9
000151–50–8
025321–22–6
000095–50–1
00541–73–1
00106–46–7
000123–91–1
007783–065–4
000071–55–6
000075–01–4
* Denotes new profile
Dated: November 17, 2006.
Ken Rose,
Acting Director, Office of Policy, Planning
and Evaluation, National Center for
Environmental Health/Agency for Toxic
Substances and Disease Registry.
[FR Doc. E6–19857 Filed 11–22–06; 8:45 am]
BILLING CODE 4163–70–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
cprice-sewell on PROD1PC66 with NOTICES
Centers for Disease Control and
Prevention
Request for Nominations of
Candidates to Serve on the Advisory
Committee on Immunization Practices,
Centers for Disease Control and
Prevention, Department of Health and
Human Services
The Centers for Disease Control and
Prevention (CDC) is soliciting
VerDate Aug<31>2005
13:24 Nov 22, 2006
Jkt 211001
nominations for possible membership
on the Advisory Committee on
Immunization Practices (ACIP). This
committee provides advice and
guidance to the Secretary, Department
of Health and Human Services (HHS),
and the Director, CDC, regarding the
most appropriate application of antigens
and related agents for effective
communicable disease control in the
civilian population. The committee
reviews and reports regularly on
immunization practices and
recommends improvements in the
national immunization efforts.
The committee also establishes,
reviews, and as appropriate, revises the
list of vaccines for administration to
children eligible to receive vaccines
through the Vaccines for Children (VFC)
Program.
Nominations are being sought for
individuals who have expertise and
qualifications necessary to contribute to
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
the accomplishments of the committee’s
objectives. Nominees will be selected
based upon expertise in the field of
immunization practices; multidisciplinary expertise in public health;
expertise in the use of vaccines and
immunologic agents in both clinical and
preventive medicine; knowledge of
vaccine development, evaluation, and
vaccine delivery; or knowledge about
consumer perspectives and/or social
and community aspects of
immunization programs. Federal
employees will not be considered for
membership. Members may be invited
to serve for up to four-year terms.
Consideration is given to
representation from diverse geographic
areas, both genders, ethnic and minority
groups, and the disabled. Nominees
must be U.S. citizens.
The following information must be
submitted for each candidate: name,
affiliation, address, telephone number,
E:\FR\FM\24NON1.SGM
24NON1
]]>Agencies
[Federal Register Volume 71, Number 226 (Friday, November 24, 2006)]
[Notices]
[Pages 67871-67872]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-19857]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Toxic Substances and Disease Registry
[ATSDR-226]
Availability of Final Toxicological Profiles
AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR),
Department of Health and Human Services (HHS).
ACTION: Notice of availability.
-----------------------------------------------------------------------
SUMMARY: This notice announces the availability of one new and five
updated final toxicological profiles of priority hazardous substances
comprising the eighteenth set prepared by ATSDR.
FOR FURTHER INFORMATION CONTACT: Ms. Olga Dawkins, Division of
Toxicology and Environmental Medicine, Agency for Toxic Substances and
Disease Registry, Mailstop F-32, 1600 Clifton Road, NE., Atlanta,
Georgia 30333, telephone (770) 488-3315. Electronic access to these
documents is also
[[Page 67872]]
available at the ATSDR Web site: https://www.atsdr.cdc.gov/toxpro2.html.
SUPPLEMENTARY INFORMATION: The Superfund Amendments and Reauthorization
Act of 1986 (SARA) (42 U.S.C. 9601 et seq.) amended the Comprehensive
Environmental Response, Compensation, and Liability Act of 1980 (CERCLA
or Superfund) (42 U.S.C. 9601 et seq.) by establishing certain
requirements for ATSDR and the U.S. Environmental Protection Agency
(EPA) with regard to hazardous substances that are most commonly found
at facilities on the CERCLA National Priorities List (NPL). Among these
statutory requirements is a mandate for the Administrator of ATSDR to
prepare toxicological profiles for each substance included on the
priority lists of hazardous substances. These lists identified 275
hazardous substances that ATSDR and EPA determined pose the most
significant potential threat to human health. The availability of the
revised list of the 275 priority substances was announced in the
Federal Register on December 7, 2005 (70 FR 234). For prior versions of
the list of substances, see Federal Register notices dated April 17,
1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989
(54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR
52166); October 28, 1992 (57 FR 48801); February 28, 1994 (59 FR 9486);
April 29, 1996 (61 FR 18744; November 17, 1997 (62 FR 61332); October
21, 1999 (64 FR 56792); October 25, 2001 (66 FR 54014) and November 7,
2003 (68 FR 63098).
Notice of the availability of drafts of these five updated and one
new toxicological profiles for public review and comment was published
in the Federal Register on October 22, 2004, (69 FR 62049), with notice
of a 90-day public comment period for each profile, starting from the
actual release date. Following the close of the comment period,
chemical-specific comments were addressed, and, where appropriate,
changes were incorporated into each profile. The public comments and
other data submitted in response to the Federal Register notices bear
the docket control number ATSDR-205. This material is available for
public inspection at the Division of Toxicology and Environmental
Medicine, Agency for Toxic Substances and Disease Registry, 1825
Century Boulevard, Atlanta, Georgia (not a mailing address), between 8
a.m. and 4:30 p.m., Monday through Friday, except legal holidays.
Availability
This notice announces the availability of one new and five updated
final toxicological profiles of priority hazardous substances
comprising the eighteenth set prepared by ATSDR.
The following toxicological profiles are now available through the
U.S. Department of Commerce, National Technical Information Service
(NTIS), 5285 Port Royal Road, Springfield, Virginia 22161, telephone 1-
800-553-6847. There is a charge for these profiles as determined by
NTIS.
Eighteenth Set:
------------------------------------------------------------------------
Toxicological profile NTIS Order No. CAS No.
------------------------------------------------------------------------
1. Cyanide, Hydrogen cyanide, Sodium PB2007-100674 000057-12-5
cyanide, Potassium cyanide.......... 000074-90-8
000143-33-9
000151-50-8
2. Dichlorobenzenes, 1, 2- PB2007-100672 025321-22-6
Dichlorobenzene, 1,3- 000095-50-1
Dichlorobenzene, 1,4-Dichlorobenzene 00541-73-1
00106-46-7
3. 1, 4-Dioxane *.................... PB2007-100676 000123-91-1
4. Hydrogen Sulfide.................. PB2007-100675 007783-065-4
5. 1, 1, 1-Trichloroethane........... PB2007-100673 000071-55-6
6. Vinyl Chloride.................... PB2007-100671 000075-01-4
------------------------------------------------------------------------
* Denotes new profile
Dated: November 17, 2006.
Ken Rose,
Acting Director, Office of Policy, Planning and Evaluation, National
Center for Environmental Health/Agency for Toxic Substances and Disease
Registry.
[FR Doc. E6-19857 Filed 11-22-06; 8:45 am]
BILLING CODE 4163-70-P
